Publications by authors named "B L Schorr"
Right anterior insula ASL hypoperfusion as a diagnostic biomarker of prodromal and mild dementia with Lewy bodies: preliminary evidence using a Bayesian approach.
Geroscience
August 2024
Identifying and validating a biomarker with high specificity in early-stage dementia with Lewy bodies (DLB) using a feasible method is crucial to enhance the current suboptimal diagnostic procedure. Previous research revealed abnormalities, including hypoperfusion in the right anterior insular cortex at group level, in prodromal DLB. Exploring hypoperfusion of the right anterior insula, at an individual-level and assessing its relevance as a potential imaging biomarker in early DLB, has, to our knowledge, not been investigated.
View Article and Find Full Text PDFArticle Synopsis
- Research indicates that plasma biomarkers related to amyloid, tau, neurodegeneration, and neuroinflammation could be useful in diagnosing dementia, but their effectiveness for diagnosing dementia with Lewy bodies (DLB) specifically remains unclear.
- A study involving patients with DLB, Alzheimer's disease (AD), and neurological controls measured various plasma biomarkers and found that DLB patients had altered biomarker levels compared to controls and AD patients.
- Plasma p-tau181 was the most effective biomarker for distinguishing DLB from AD and controls, suggesting it plays a key role in identifying amyloid-related issues in DLB, although the overall diagnostic performance of these biomarkers was moderate.
Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are often associated with depressive symptoms from the prodromal stage. The aim of the present study was to investigate the neuroanatomical correlates of depression in prodromal to mild DLB patients compared with AD patients. Eighty-three DLB patients, 37 AD patients, and 18 healthy volunteers were enrolled in this study.
View Article and Find Full Text PDFBackground: Childhood Attention-deficit/hyperactivity disorder (C-ADHD) is a neurodevelopmental disorder, associated with an increased risk of subsequent schizophrenia. The objective of the present study was to determine the prevalence of C-ADHD in schizophrenia and the clinical and cognitive characteristics associated with C-ADHD history in schizophrenia.
Methods: 569 subjects with schizophrenia (74 % men, mean age 30.
Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial - CADOT.
Front Psychiatry
September 2023
Article Synopsis
- The study focuses on treatment-resistant depression (TRD) characterized by anergic-anhedonic symptoms, proposing a two-step therapy called the Dopaminergic Antidepressant Therapy Algorithm (DATA) combining monoamine oxidase inhibitors and dopamine D2 receptor agonists.
- Out of 52 patients treated with DATA, 48 were analyzed, showing significant remission rates: 52% after the first step and 77% after the second, highlighting the effectiveness of this approach over a median follow-up of 4 months.
- The findings suggest that TRD patients respond well to pro-dopaminergic treatments, but some variability in patient responses indicates a need for better understanding of dopamine-sensitive depression forms.